Stephens Reiterates Equal Weight Rating for Lifecore Biomedical (NASDAQ:LFCR)

Lifecore Biomedical (NASDAQ:LFCR)‘s stock had its “equal weight” rating reaffirmed by equities research analysts at Stephens in a research note issued to investors on Friday,Benzinga reports. They currently have a $6.00 price objective on the stock. Stephens’ target price points to a potential downside of 21.26% from the company’s current price.

Separately, Craig Hallum increased their target price on Lifecore Biomedical from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, November 22nd.

Lifecore Biomedical Trading Up 14.4 %

NASDAQ:LFCR opened at $7.62 on Friday. Lifecore Biomedical has a 12-month low of $3.68 and a 12-month high of $8.90. The company has a current ratio of 1.83, a quick ratio of 0.80 and a debt-to-equity ratio of 12.90. The stock’s 50 day simple moving average is $7.03 and its 200-day simple moving average is $5.80. The firm has a market cap of $280.62 million, a P/E ratio of 95.25 and a beta of 0.98.

Lifecore Biomedical (NASDAQ:LFCR) last released its earnings results on Thursday, January 2nd. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.02. Lifecore Biomedical had a net margin of 5.09% and a negative return on equity of 382.65%. Equities analysts anticipate that Lifecore Biomedical will post -0.99 EPS for the current year.

Hedge Funds Weigh In On Lifecore Biomedical

Large investors have recently made changes to their positions in the stock. Marshall Wace LLP grew its position in Lifecore Biomedical by 87.3% during the second quarter. Marshall Wace LLP now owns 300,120 shares of the company’s stock worth $1,540,000 after buying an additional 139,887 shares during the period. State Street Corp grew its holdings in shares of Lifecore Biomedical by 10.2% in the 3rd quarter. State Street Corp now owns 334,360 shares of the company’s stock worth $1,648,000 after acquiring an additional 30,916 shares during the period. BNP Paribas Financial Markets increased its stake in Lifecore Biomedical by 2,640.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 54,399 shares of the company’s stock valued at $268,000 after purchasing an additional 52,414 shares in the last quarter. Rhumbline Advisers increased its stake in Lifecore Biomedical by 1,668.5% in the 2nd quarter. Rhumbline Advisers now owns 26,899 shares of the company’s stock valued at $138,000 after purchasing an additional 25,378 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in Lifecore Biomedical during the second quarter worth $56,000. Hedge funds and other institutional investors own 83.36% of the company’s stock.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.